Literature DB >> 8448072

A comparison of the effects of captopril and enalapril on skin responses to intradermal bradykinin and skin blood flow in the human forearm.

T C Li Kam Wa1, E D Cooke, P Turner.   

Abstract

1. The effects of captopril and enalapril on skin responses to intradermal injections of bradykinin and skin blood flow in the forearm were investigated in this randomised, double-blind, placebo-controlled, cross-over study. 2. Intradermal injections of 0, 1, 2.5 and 5 micrograms of bradykinin in 0.9% sodium chloride were made into the forearm of twelve healthy volunteers before and at 2, 6 and 24 h after single oral doses of 25 mg captopril, 10 mg enalapril or placebo. Forearm skin blood flow was measured by the technique of laser Doppler flowmetry (LDF) before the injections were made and the skin responses evaluated at 15 min after injections of bradykinin by measurement of cutaneous blood flow outside the induced weal, erythema area and weal volume. 3. The bradykinin-induced cutaneous responses measured by LDF, erythema area and weal volume increased with incremental bradykinin dose. Compared with placebo, captopril significantly augmented the cutaneous vasodilator effects of bradykinin, measured by LDF and erythema area, at 2 h and the weal responses at 2 and 6 h. Enalapril enhanced the vasodilator responses to bradykinin at 2 and 6 h and the weal responses at 2, 6 and 24 h. Neither captopril nor enalapril significantly affected forearm skin blood flow. 4. This study showed that captopril and enalapril potentiated the effects of intradermal bradykinin both with respect to blood flow changes and weal formation in keeping with effective kininase II inhibition and the time course of these changes are consistent with enalapril being a longer acting drug than captopril. Captopril and enalapril exerted no influence on forearm skin blood flow measured by LDF.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8448072      PMCID: PMC1381483          DOI: 10.1111/j.1365-2125.1993.tb05663.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  35 in total

1.  Skin blood flow changes following intradermal bradykinin injections measured by laser Doppler flowmetry: comparison with weal and flare.

Authors:  T C Li Kam Wa; N E Almond; E D Cooke; P Turner
Journal:  J Med Eng Technol       Date:  1990 Sep-Oct

2.  The effect of converting enzyme inhibition with SQ20,881 on plasma and urinary kinins, prostaglandin E, and angiotensin II in hypertensive man.

Authors:  J M Vinci; D Horwitz; R M Zusman; J J Pisano; K J Catt; H R Keiser
Journal:  Hypertension       Date:  1979 Jul-Aug       Impact factor: 10.190

3.  Laser Doppler measurement of cutaneous blood flow.

Authors:  G A Holloway; D W Watkins
Journal:  J Invest Dermatol       Date:  1977-09       Impact factor: 8.551

4.  A dipeptidyl carboxypeptidase that converts angiotensin I and inactivates bradykinin.

Authors:  H Y Yang; E G Erdös; Y Levin
Journal:  Biochim Biophys Acta       Date:  1970-08-21

5.  Differences in response to the peptidyldipeptide hydrolase inhibitors SQ 20,881 and SQ 14,225 in normal-renin essential hypertension.

Authors:  F R Crantz; S L Swartz; N K Hollenberg; T J Moore; R G Dluhy; G H Williams
Journal:  Hypertension       Date:  1980 Sep-Oct       Impact factor: 10.190

6.  Continuous measurement of tissue blood flow by laser-Doppler spectroscopy.

Authors:  M D Stern; D L Lappe; P D Bowen; J E Chimosky; G A Holloway; H R Keiser; R L Bowman
Journal:  Am J Physiol       Date:  1977-04

7.  Endocrine profile in the long-term phase of converting-enzyme inhibition.

Authors:  S L Swartz; G H Williams; N K Hollenberg; F R Crantz; T J Moore; L Levine; A A Sasahara; R G Dluhy
Journal:  Clin Pharmacol Ther       Date:  1980-10       Impact factor: 6.875

8.  Role of prostaglandin-mediated vasodilatation in inflammation.

Authors:  T J Williams; M J Peck
Journal:  Nature       Date:  1977-12-08       Impact factor: 49.962

9.  The effect of the converting enzyme inhibitor SQ 20.881 on kinins, renin-angiotensin-aldosterone and catecholamines in relation to blood pressure in hypertensive patients.

Authors:  L Hulthén; B Hökfelt
Journal:  Acta Med Scand       Date:  1978

10.  A specific orally active inhibitor of angiotensin-converting enzyme in man.

Authors:  R K Ferguson; G A Turini; H R Brunner; H Gavras; D N McKinstry
Journal:  Lancet       Date:  1977-04-09       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.